These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7828385)

  • 1. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group.
    Locker PK; Jungbluth GL; Francom SF; Hughes GS
    Clin Pharmacol Ther; 1995 Jan; 57(1):73-88. PubMed ID: 7828385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
    Berthold HK; Sudhop T; von Bergmann K; Gouni-Berthold I
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):364-72. PubMed ID: 20693157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H; Rhyne J; Abby S; Lai YL; Jones M
    Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
    Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
    Insull W; Davidson MH; Kulkarni PM; Siddhanti S; Ciaccia AV; Keech CA
    Metabolism; 2005 Jul; 54(7):939-46. PubMed ID: 15988705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study.
    MacMahon M; Carless J
    J Cardiovasc Risk; 1998 Jun; 5(3):167-72. PubMed ID: 10201553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
    Reyna-Villasmil N; Bermúdez-Pirela V; Mengual-Moreno E; Arias N; Cano-Ponce C; Leal-Gonzalez E; Souki A; Inglett GE; Israili ZH; Hernández-Hernández R; Valasco M; Arraiz N
    Am J Ther; 2007; 14(2):203-12. PubMed ID: 17414591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group.
    Rubenfire M; Maciejko JJ; Blevins RD; Orringer C; Kobylak L; Rosman H
    Arch Intern Med; 1991 Nov; 151(11):2234-40. PubMed ID: 1953228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.